References

rpcardio

Rational Pharmacotherapy in Cardiology

Рациональная Фармакотерапия в Кардиологии

1819-64462225-3653

«SILICEA-POLIGRAF» LLC

rpcardio-1080

Research Article

Articles

Статьи

ДИАГНОСТИКА И ЛЕЧЕНИЕ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ. РЕКОМЕНДАЦИИ ВНОК И ВНОА, 2011 Г.

Редакционная

статья

2011

28012016

74580

2016

Редакционная с.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.rpcardio.online/jour/article/view/1080

References1

Fuster V., Ryden L.E., Cannom D.S., et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). JACC 2006; 48: 854-906.

Оганов Р.Г., Салимов В.А., Бокерия Л.А., и др. Клинические рекомендации по диагностике и лечению пациентов с фибрилляцией предсердий. Вестник аритмологии 2010; №59: 53-77.

Camm A.J., Kirchhof P., Lip G.Y.H., et al. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429.

Wann S., Curtis A.B., January C.T., et al. 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline). A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 123: 104-123.

Wann L.S., Curtis A.B., Ellenbogen K.A., et al. 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on Dabigatran) A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 123: 1144-1150.

Stewart S., Hart C.L., Hole D.J., McMurray J.J. Population prevalence, incidence, and predictors of atrial ﬁbrillation in the Renfrew/Paisley study. Heart 2001; 86: 516–521.

Go A.S., Hylek E.M., Phillips K.A., et al. Prevalence of diagnosed atrial ﬁbrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370–2375.

Kirchhof P., Auricchio A., Bax J., et al. Outcome parameters for trials in atrial ﬁbrillation: executive summary. Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NET-work (AFNET) and the European Heart Rhythm Association (EHRA). Eur Heart J 2007; 28: 2803–2817.

Lip G.Y., Golding D.J., Nazir M., et al. A survey of atrial ﬁbrillation in general practice: the West Birmingham Atrial Fibrillation Project. Br J Gen Pract 1997; 47: 285–289.

Miyasaka Y., Barnes M.E., Gersh B.J., et al. Secular trends in incidence of atrial ﬁbrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114: 119–125.

Heeringa J., van der Kuip D.A., Hofman A., et al. Prevalence, incidence and lifetime risk of atrial ﬁbrillation: the Rotterdam study. Eur Heart J 2006; 27: 949–953.

Naccarelli G.V., Varker H., Lin J., Schulman K.L. Increasing prevalence of atrial ﬁbril-lation and ﬂutter in the United States. Am J Cardiol 2009; 104: 1534–1539.

Lloyd-Jones D.M., Wang T.J., Leip E.P., et al. Lifetime risk for development of atrial ﬁbrillation: the Framingham Heart Study. Circulation 2004; 110: 1042–1046.

Stewart S., Hart C.L., Hole D.J., McMurray J.J. A population-based study of the long-term risks associated with atrial ﬁbrillation: 20-year follow-up of the Renfrew/ Paisley study. Am J Med 2002; 113: 359–364.

Hylek E.M., Go A.S., Chang Y., et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial ﬁbrillation. N Engl J Med 2003; 349: 1019–1026.

Knecht S., Oelschlager C., Duning T., et al. Atrial ﬁbrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. Eur Heart J 2008; 29: 2125–2132.

Friberg L., Hammar N., Rosenqvist M. Stroke in paroxysmal atrial ﬁbrillation: report from the Stockholm Cohort of Atrial Fibrillation. Eur Heart J 2010; 31: 967–975.

Thrall G., Lane D., Carroll D., Lip G.Y. Quality of life in patients with atrial ﬁbrilla-tion: a systematic review. Am J Med 2006; 119: 448 e1–e19.

Nieuwlaat R., Capucci A., Camm A.J., et al. Atrial ﬁbrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005; 26: 2422–2434.

Nabauer M., Gerth A., Limbourg T., et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace 2009; 11: 423–434.

Sanchez P.L., Fernandez-Aviles F. Structural heart disease: a new chapter in cardiovascular disease. ESC Mono-graphic issue: Structural Heart Disease. Ed. Ruiz C.E. eur Heart j 2010; 12 (suppl. E): e1.

Maron B.J., Towbin J.A., Thiene G., et al. Contemporary deﬁnitions and classiﬁcation of the cardiomyopathies: an American Heart Association Scientiﬁc Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006; 113: 1807–1816.

Goette A., Bukowska A., Dobrev D., et al. Acute atrial tachyarrhythmia induces angiotensin II type 1 receptor-mediated oxidative stress and microvascular ﬂow abnormalities in the ventricles. Eur Heart J 2009; 30: 1411–1420.

Schotten U., Verheule S., Kirchhof P., Goette A. Pathophysiological mechanisms of atrial ﬁbrillation—a translational appraisal. Physiol Rev 2010; in press.

Daoud E.G., Bogun F., Goyal R., et al. Effect of atrial ﬁbrillation on atrial refractoriness in humans. Circulation 1996; 94: 1600–1606.

Frustaci A., Chimenti C., Bellocci F., et al. Histological substrate of atrial biopsies in patients with lone atrial ﬁbrillation. Circulation 1997; 96: 1180–1184.

Haissaguerre M., Jais P., Shah D.C., et al. Spontaneous initiation of atrial ﬁbrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339: 659–666.

Fox C.S., Parise H., D’Agostino R.B. Sr, et al. Parental atrial ﬁbrillation as a risk factor for atrial ﬁbrillation in offspring. JAMA 2004; 291: 2851–2855.

Kirchhof P., Bax J., Blomstrom-Lundquist C., et al. Early and comprehensive management of atrial ﬁbrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference ‘Research perspectives in AF’. Eur Heart J 2009; 30: p2969–2977c.

Hodgson-Zingman D.M., Karst M.L., Zingman L.V., et al. Atrial natriuretic peptide frameshift mutation in familial atrial ﬁbrillation. N Engl J Med 2008; 359: 158–165.

Olson T.M., Michels V.V., Ballew J.D., et al. Sodium channel mutations and susceptibility to heart failure and atrial ﬁbrillation. JAMA 2005; 293: 447–454.

Chen Y.H., Xu S.J., Bendahhou S., et al. KCNQ1 gain-of-function mutation in familial atrial ﬁbrillation. Science 2003; 299: 251–254.

Gudbjartsson D.F., Holm H., Gretarsdottir S., et al. A sequence variant in ZFHX3 on 16q22 associates with atrial ﬁbrillation and ischemic stroke. Nat Genet 2009; 41: 876–878.

Packer D.L., Bardy G.H., Worley S.J., et al. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol 1986; 57: 563–570.

Watson T., Shantsila E., Lip G.Y. Mechanisms of thrombogenesis in atrial ﬁbrillation: Virchow’s triad revisited. Lancet 2009; 373: 155–166.

Blomstrom-Lundqvist C., Scheinman M.M., Aliot E.M., et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias—executive summary. a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society. JACC 2003; 42: 1493–14531.

Hobbs FD, Fitzmaurice DA, Mant J, Murray E, Jowett S, Bryan S, Raftery J, Davies M, Lip G. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial ﬁbrillation in people aged 65 and over. The SAFE study. Health Technol Assess 2005;9:iii–iv, ix–x, 1–74.

Jahangir A, Lee V, Friedman PA, Trusty JM, Hodge DO, Kopecky SL, Packer DL, Hammill SC, Shen WK, Gersh BJ. Long-term progression and outcomes with aging in patients with lone atrial ﬁbrillation: a 30-year follow-up study. Circulation 2007;115:3050–3056.

Calkins H., Brugada J., Packer D.L., et al. HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Personnel, Policy, Procedures and Follow-Up: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation developed in partnership with the European Heart Rhythm Association (EHRA) and the European Cardiac Arrhythmia Society (ECAS); in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). Endorsed and approved by the governing bodies of the American College of Cardiology, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, and the Heart Rhythm Society. Europace 2007; 9: 335–379.

Jabaudon D., Sztajzel J., Sievert K., et al. Usefulness of ambulatory 7-day ECG monitoring for the detection of atrial ﬁbrillation and ﬂutter after acute stroke and transient ischemic attack. Stroke 2004; 35: 1647–1651.

Hindricks G., Piorkowski C., Tanner H., et al. Perception of atrial ﬁbrillation before and after radiofrequency catheter ablation: relevance of asymptomatic arrhythmia recurrence. Circulation 2005; 112: 307–313.

Israel C.W., Gronefeld G., Ehrlich J.R., et al. Long-term risk of recurrent atrial ﬁbrillation as documented by an implantable monitoring device: implications for optimal patient care. J Am Coll Cardiol 2004; 43: 47–52.

Ziegler P.D., Koehler J.L., Mehra R. Comparison of continuous versus intermittent monitoring of atrial arrhythmias. Heart Rhythm 2006; 3: 1445–1452.

Binici Z., Intzilakis T., Nielsen O.W., et al. Excessive Supraventricular ectopic activity and increased risk of atrial ﬁbrillation and stroke. Circulation 2010; 121: 1904–1911.

Brignole M., Vardas P., Hoffman E., et al. Indications for the use of diagnostic implantable and external ECG loop recorders. Europace 2009; 11: 671–687.

Hindricks G., Pokushalov E., Urban L., et al. Performance of a new leadless implantable cardiac monitor in detecting and quantifying atrial ﬁbrillation—results of the XPECT trial. Circ Arrhythm Electrophysiol 2010; 3: 141–147.

Dorian P., Guerra P.G., Kerr C.R., et al. Validation of a new simple scale to measure symptoms in atrial ﬁbrillation: the Canadian Cardiovascular Society Severity in Atrial Fibrillation scale. Circ Arrhythm Electrophysiol 2009; 2: 218–224.

Klein A.L., Grimm R.A., Murray R.D., et al. Stoddard MF. Use of transesophageal echocardiography to guide car-dioversion in patients with atrial ﬁbrillation. N Engl J Med 2001; 344: 1411–1420.

Fitzmaurice D.A., Hobbs F.D., Jowett S., et al. Screening versus routine practice in detection of atrial ﬁbrillation in patients aged 65 or over: cluster randomised controlled trial. BMJ 2007; 335: 383.

Dickstein K., Cohen-Solal A., Filippatos G., et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29: 2388–2442.

Haverkamp W., Breithardt G., Camm A.J., et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur Heart J 2000; 21: 1216–1231.

Singh B.N., Singh S.N., Reda D.J., et al. Amiodarone versus sotalol for atrial ﬁbrillation. N Engl J Med 2005; 352: 1861–1872.

Hughes M., Lip G.Y. Stroke and thromboembolism in atrial ﬁbrillation: a systematic review of stroke risk factors, risk stratiﬁcation schema and cost effectiveness data. Thromb Haemost 2008; 99: 295–304.

Stroke in AF working group. Independent predictors of stroke in patients with atrial ﬁbrillation: a systematic review. Neurology 2007; 69: 546–554.

Schmitt J., Duray G., Gersh B.J., Hohnloser S.H. Atrial ﬁbrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J 2009; 30: 1038–1045.

Gage B.F., Waterman A.D., Shannon W., et al. Validation of clinical classiﬁcation schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864–2870.

Go A.S., Hylek E.M., Chang Y., et al. Anticoagulation therapy for stroke prevention in atrial ﬁbrillation: how well do randomized trials translate into clinical practice? JAMA 2003; 290: 2685–2692.

Lip G.Y., Nieuwlaat R., Pisters R., et al. Reﬁning clinical risk stratiﬁcation for predicting stroke and thromboembolism in atrial ﬁbrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial ﬁbrillation. Chest 2010; 137: 263–272.

Lip G.Y., Frison L., Halperin J., Lane D. Identifying patients at risk of stroke despite anticoagulation. Stroke 2010; in press.

Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial ﬁbrillation. Ann Intern Med 2007; 146: 857–867.

Sato H., Ishikawa K., Kitabatake A., et al. Low-dose aspirin for prevention of stroke in low-risk patients with atrial ﬁbrillation: Japan Atrial Fibrillation Stroke Trial. Stroke 2006; 37: 447–451.

Mant J., Hobbs F.D., Fletcher K., et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial ﬁbrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370: 493–503.

Connolly S.J., Pogue J., Hart R., et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial ﬁbrillation in the Atrial ﬁbrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367: 1903–1912.

Connolly S.J., Pogue J, Hart R.G., et al. Effect of clopidogrel added to aspirin in patients with atrial ﬁbrillation. N Engl J Med 2009; 360: 2066–2078.

Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial ﬁbrillation. N Engl J Med 2009; 361: 1139–1151.

O'Riordan M. Off orbit? ROCKET AF: Rivaroxaban noninferior to warfarin, but superiority analyses at odds. До-ступно в Интернет по адресу: http://www.theheart.org/article/1148785.do

Connolly S.J., Eikelboom J., Joyner C., et al., for the AVERROES Steering Committee and Investigators. Apixa-ban in Patients with Atrial Fibrillation. N Engl J Med 2011; 364: 806-817.

Pisters R., Lane D.A., Nieuwlaat R., et al. A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial ﬁbrillation patients: The Euro Heart Survey. Chest 2010; March 18 [Epub ahead of print].

Lip G.Y., Huber K., Andreotti F., et al. Management of antithrombotic therapy in atrial ﬁbrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Thromb Haemost 2010; 103: 13–28.

Nagarakanti R., Ezekowitz M.D., Oldgren J., et al. Dabigatran Versus Warfarin in Patients With Atrial Fibrillation. An Analysis of Patients Undergoing Cardioversion. Circulation 2011; 123: 131-136.

Murray R.D., Deitcher S.R., Shah A., et al. Potential clinical efficacy and cost benefit of a transesophageal echocardiography-guided low-molecular-weight heparin (enoxaparin) approach to antithrombotic therapy in patients undergoing immediate cardioversion from atrial fibrillation. J Am Soc Echocardiogr 2001; 14: 200-208.

Stellbrink C., Nixdorff U., Hofmann T., et al.; on Behalf of the ACE (Anticoagulation in Cardioversion using Enoxaparin) Study Group. Safety and Efficacy of Enoxaparin Compared With Unfractionated Heparin and Oral Anticoagulants for Prevention of Thromboembolic Complications in Cardioversion of Nonvalvular Atrial Fibrillation. The Anticoagulation in Cardioversion using Enoxaparin (ACE) Trial. Сirculation 2004; 109: 997-1003.

Holmes D.R., Reddy V.Y., Turi Z.G., et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial ﬁbrillation: a randomised non-inferiority trial. Lancet 2009; 374: 534–542.

Singer D.E., Albers G.W., Dalen J.E., et al. Antithrombotic therapy in atrial ﬁbrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 546S–592S.

Vahanian A., Baumgartner H., Bax J., et al. Guidelines on the management of valvular heart disease: the Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007; 28: 230–268.

Fang M.C., Go A.S., Hylek E.M., et al. Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial ﬁbrillation study. J Am Geriatr Soc 2006; 54: 1231–1236.

Poldermans D., Bax J.J., Boersma E., et al. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: the Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA). Eur J Anaesthesiol 2010; 27: 92–137.

Alboni P., Botto G.L., Baldi N., et al. Outpatient treatment of recent-onset atrial ﬁbrillation with the ‘pill-in-the-pocket’ approach. N Engl J Med 2004; 351: 2384–2391.

Kowey P.R., Dorian P., Mitchell L.B., et al. Vernakalant hydrochloride for the rapid conversion of atrial ﬁbrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol 2009; 2: 652–659.

Roy D., Pratt C.M., Torp-Pedersen C., et al. Vernakalant hydrochloride for rapid conversion of atrial ﬁbrillation: a phase 3, randomized, placebo-controlled trial. Circulation 2008; 117: 1518–1525.

Camm A.J., Capucci A., Hohnloser S., et al. A randomized active-controlled study comparing the efﬁcacy and safety of vernakalant to amiodarone in recent onset atrial ﬁbrillation. JACC 2010; in press.

Сулимов В. А., Гиляров. М. Ю. Применение нового отчественного антиаритмического препарата III класса нибентана для устранения пароксизмальной формы фибрилляции предсердий. Российский кардиологический журнал 2002: № 6: 49-55.

Шубик Ю.В., Медведев М.М., Ривин А.Е. Нибентан: препарат для фармакологической кардиоверсии при персистирующей форме фибрилляции предсердий. Кардиология 2005; №2: 19-24.

Попов С.В., Аубакирова Г.А., Антонченко И.В. и др. Эффективность антиаритмического препарата III класса нибентана у больных с фибрилляцией предсердий. Вестник аритмологии 2003; 31: 10-14.

Брегвадзе И.Н., Майков Е.Б., Бильдинов О.А. и др. Эффективность и безопасность нибентана при медикаментозной кардиоверсии у больных с персистирующей формой фибрилляции предсердий: роль ограничения доз препарата и применения магния сульфата. Кардиология 2007; 3: 48-55.

Halpern S.W., Ellroot G., Singh B.N., Mandel W.J. Efficacy of intravenous procainamid infusion in converting atrial fibrillation to sinus rhythm. Relation to left atrium size. Brit Heart J 1980; 44: 589-595.

Fenster P.E., Comess K.A., Marsh A., et al. Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion. Am Heart J 1983; 106: 501-504.

Kochiadakis G.E., Igoumenidis N.E., Solomou M.C., et al. Conversion of atrial fibrillation to sinus rhythm using acute intravenous procainamide infusion. Cardiovasc Drugs Ther 1998; 12: 75-81.

Kochiadakis G.E., Igoumenidis N.E., Hamilos M.E., et al. A comparative study of the efficacy and safety of pro-cainamide versus propafenone versus amiodarone for the conversion of recent-onset atrial fibrillation. Am J Cardiol 2007; 99: 1721-1725.

Stiell I.G., Clement C.M., Symington C., et al. Emergency department use of intravenous procainamide for patients with acute atrial fibrillation or flutter. Acad Emerg Med 2007; 14: 1158-1164.

Чазов Е.И., Голицын С.П. Руководство по нарушениям ритма сердца. ГЭОТАР-Медиа, 2008.

Reisinger J., Gatterer E., Lang W., et al. Flecainide versus ibutilide for immediate cardioversion of atrial ﬁbrillation of recent onset. Eur Heart J 2004; 25: 1318–1324.

Khan I.A. Single oral loading dose of propafenone for pharmacological cardiover-sion of recent-onset atrial ﬁbrillation. JACC 2001; 37: 542–547.

Martinez-Marcos F.J., Garcia-Garmendia J.L., Ortega-Carpio A., et al. Comparison of intravenous ﬂecainide, propafenone, and amiodarone for conversion of acute atrial ﬁbrillation to sinus rhythm. Am J Cardiol 2000; 86: 950–953.

Chevalier P., Durand-Dubief A., Burri H., et al. Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial ﬁbrillation: a meta-analysis. JACC 2003; 41: 255–262.

Vardas P.E., Kochiadakis G.E., Igoumenidis N.E., et al. Amiodarone as a ﬁrst-choice drug for restoring sinus rhythm in patients with atrial ﬁbrillation: a randomized, controlled study. Chest 2000; 117: 1538–1545.

Bianconi L., Castro A., Dinelli M., et al. Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial ﬁbrillation and ﬂutter. A multicentre, randomized, double-blind, placebo-controlled study. Eur Heart J 2000; 21: 1265–1273.

Stambler B.S., Wood M.A., Ellenbogen K.A. Antiarrhythmic actions of intravenous ibutilide compared with pro-cainamide during human atrial ﬂutter and ﬁbrillation: electrophysiological determinants of enhanced conversion efﬁcacy. Circulation 1997; 96: 4298–4306.

Востриков В.А. Эффективность и безопасность электроимпульсной терапии фибрилляции предсердий. В кн.: Методы нелинейного анализа в кардиологии и онкологии. Под редакцией Р.З. Назирова. Из-во Университет книжный дом, 2010, стр. 73-79.

100

Kirchhof P., Eckardt L., Loh P., et al. Anterior–posterior versus anterior–lateral electrode positions for external cardioversion of atrial ﬁbrillation: a randomised trial. Lancet 2002; 360: 1275–1279.

101

Oral H., Souza J.J., Michaud G.F., et al. Facilitating transthoracic cardioversion of atrial ﬁbrillation with ibutilide pretreatment. N Engl J Med 1999; 340: 1849–1854.

102

Manios E.G., Mavrakis H.E., Kanoupakis E.M., et al. Effects of amiodarone and diltiazem on persistent atrial ﬁbrillation conversion and recurrence rates: a randomized controlled study. Cardiovasc Drugs Ther 2003; 17: 31–39.

103

Bianconi L., Mennuni M., Lukic V., et al. Effects of oral propafenone administration before electrical cardioversion of chronic atrial ﬁbrillation: a placebo-controlled study. JACC 1996; 28: 700–706.

104

Roy D., Talajic M., Dorian P. et al. Amiodaron to prevent recurrence of atrial fibrillation. N Engl J Med 2000; 342: 913-920.

105

Кадырова М.М. Автореферат диссертации на соискание ученой степени кандидата медицинских наук

106

«Антиаритмические и гемодинамические эффекты аллапинина у больных с мерцательной аритмией до и после восстановления синусового ритма в сравнении с хинидином бисульфатом». Москва, 1990. 106. Бунин Ю.А., Фирстова М.И., Енукашвили Р.Р. Поддерживающая антиаритмическая терапия после восстановления синусового ритма у больных с постоянной формой мерцательной аритмии. Материалы 5-го Всероссийского съезда кардиологов. Челябинск, 1996: 28.

107

Gulamhusein S., Ko P., Carruthers S.G., Klein G.J. Acceleration of the ventricular response during atrial ﬁbrillation in the Wolff–Parkinson–White syndrome after verapamil. Circulation 1982; 65: 348–354.

108

Fetsch T., Bauer P., Engberding R., et al. Prevention of atrial ﬁbrillation after cardioversion: results of the PAFAC trial. Eur Heart J 2004; 25: 1385–1394.

109

Cosio F.G., Aliot E., Botto G.L., et al. Delayed rhythm control of atrial ﬁbrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the ﬁrst detected episode. Europace 2008; 10: 21–27.

110

Kirchhof P. Can we improve outcomes in atrial ﬁbrillation patients by early therapy? BMC Med 2009; 7: 72. 111. AFFIRM Investigators. A comparison of rate control and rhythm control in patients with atrial ﬁbrillation. N Engl J Med 2002; 347: 1825–1833.

111

Van Gelder I.C., Hagens V.E., Bosker H.A., et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial ﬁbrillation. N Engl J Med 2002; 347: 1834–1840.

112

Carlsson J., Miketic S., Windeler J., et al., and the STAF Investigators. Randomized trial of rate-control versus rhythm-control in persistent atrial ﬁbrillation. J Am Coll Cardiol 2003; 41: 1690–1696.

113

Opolski G., Torbicki A., Kosior D.A., et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial ﬁbrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest 2004; 126: 476–486.

114

Roy D., Talajic M., Nattel S., et al. Rhythm control versus rate control for atrial ﬁbrillation and heart failure. N Engl J Med 2008; 358: 2667–2677.

115

Ogawa S., Yamashita T., Yamazaki T., et al. Optimal treatment strategy for patients with paroxysmal atrial ﬁbrillation: J-RHYTHM Study. Circ J 2009; 73: 242–248.

116

Hohnloser S.H., Kuck K.H., Lilienthal J. Rhythm or rate control in atrial ﬁbrilla-tion—Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000; 356: 1789–1794.

117

Hsu L.F., Jais P., Sanders P., et al. Catheter ablation for atrial ﬁbrillation in congestive heart failure. N Engl J Med 2004; 351: 2373–2383.

118

Khan M.N., Jais P., Cummings J., et al. Pulmonary-vein isolation for atrial ﬁbrillation in patients with heart failure. N Engl J Med 2008; 359: 1778–1785.

119

Hohnloser S.H., Crijns H.J., van Eickels M., et al. Effect of dronedarone on cardiovascular events in atrial ﬁbrillation. N Engl J Med 2009; 360: 668–678.

120

Wilber D.J., Pappone C., Neuzil P., et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial ﬁbrillation: a randomized controlled trial. JAMA 2010; 303: 333–340.

121

Talajic M., Khairy P., Levesque S., et al. Maintenance of sinus rhythm and survival in patients with heart failure and atrial ﬁbrillation. JACC 2010; 55: 1796–1802.

122

Van Gelder I.C., Groenveld H.F., Crijns H.J., et al. Lenient versus strict rate control in patients with atrial ﬁbrillation. N Engl J Med 2010; 362: 1363–1373.

123

Singh B.N., Connolly S.J., Crijns H.J., et al. Dronedarone for maintenance of sinus rhythm in atrial ﬁbrillation or ﬂutter. N Engl J Med 2007; 357: 987–999.

124

Segal J.B., McNamara R.L., Miller M.R., et al. The evidence regarding the drugs used for ventricular rate control. J Fam Pract 2000; 49: 47–59.

125

Hou Z.Y., Chang M.S., Chen C.Y., et al. Acute treatment of recent-onset atrial ﬁbrillation and ﬂutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study. Eur Heart J 1995; 16: 521–528.

126

Redfearn D.P., Krahn A.D., Skanes A.C., et al. Use of medications in Wolff–Parkinson–White syndrome. Expert Opin Pharmacother 2005; 6: 955–963.

127

Davy J.M., Herold M., Hoglund C., et al. Dronedarone for the control of ventricular rate in permanent atrial ﬁbrillation: the Efﬁcacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial ﬁbrillation (ERATO) study. Am Heart J 2008; 156: 527.e1–527.e9.

128

Murgatroyd F.D., Gibson S.M., Baiyan X., et al. Double-blind placebo-controlled trial of digoxin in symptomatic paroxysmal atrial ﬁbrillation. Circulation 1999; 99: 2765–2770.

129

Gasparini M., Auricchio A., Metra M., et al. Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrial ﬁbrillation. Eur Heart J 2008; 29: 1644–1652.

130

Ozcan C., Jahangir A., Friedman P.A., et al. Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial ﬁbrillation. N Engl J Med 2001; 344: 1043–1051.

131

Weerasooriya R., Davis M., Powell A., et al. The Australian intervention randomized control of rate in atrial ﬁbrillation trial (AIRCRAFT). JACC 2003; 41: 1697–1702.

132

Upadhyay G.A., Choudhry N.K., Auricchio A., et al. Cardiac resynchronization in patients with atrial ﬁbrillation: a meta-analysis of prospective cohort studies. JACC 2008; 52: 1239–1246.

133

Auricchio A., Metra M., Gasparini M., et al. Long-term survival of patients with heart failure and ventricular conduction delay treated with cardiac resynchronization therapy. Am J Cardiol 2007; 99: 232–238.

134

Dong K., Shen W.K., Powell B.D., et al. Atrioventricular nodal ablation predicts survival beneﬁt in patients with atrial ﬁbrillation receiving cardiac resynchronization therapy. Heart Rhythm 2010; Feb 17 [Epub ahead of print].

135

Lafuente-Lafuente C., Mouly S., Longas-Tejero M.A., Bergmann J.F. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial ﬁbrillation. Cochrane Database Syst Rev 2007; 4: CD005049.

136

McNamara R.L., Bass E.B., Miller M.R., et al. Management of new onset atrial ﬁbrillation (evidence report/Technology assessment). In: Agency for Heathcare Research and Quality. 2001, Publication No. AHRQ 01-E026.

137

Соколов С.Ф., Джагангиров Ф.Н. Антиаритмический препарат аллапинин: обзор результатов клинического изучения. Кардиология 2002; №7: 96–102.

138

Абдалла Аднан, Рулин В.А., Мазур Н.А. и др. Фармакокинетика и фармакодинамика нового отечественного антиаритмического препарата аллапинина. Фармакол. и токсикол. 1988; №5: 47–49.

139

Курбанов Р.Д., Абдуллаев ТА. Фармакодинамика и эффективность аллапинина у больных с нарушениями ритма сердца. Клин. Мед. 1988; №10: 52–55.

140

Сыркин А.Л., Иванов Г.Г., Аксельрод А.С. и др. Прогнозирование эффективности поддерживающей антиаритмической терапии при пароксизмальной форме фибрилляции предсердий. Кардиология и сердечно-сосудистая хирургия 2010; №4: 84-87.

141

Метелица В.И. Справочник по клинической фармакологии сердечно-сосудистых лекарственных средств. М.: МИА, 2005.

142

Соколов С.Ф., Голицын С,П., Малахов В.И. и др. Влияние аллапинина на функцию предсердно–желудочковой проводящей системы сердца. Кардиология 1988; №11: 90–95.

143

Каверина Н.В., Лысковцев В.В., Сенова З.П. и др. Этацизин: фармакологические свойства и перспективы клинического применения. Кардиология 1984; №5: 52-57.

144

Недоступ А.В., Благова О.В. Этацизин: место в лечении аритмий. Кардиология и сердечно-сосудистая хирургия 2009; №4: 62-68.

145

Кукес В.Г., Шугушев Х.Х., Гнеушев Е.Т. И др. Фармакокинетика и фармакодинамика нового антиаритмического препарата этацизина при приеме внутрь. Сов. медицина 1985; №4: 81-82.

146

Лозинский Л.Г., Замотаев И.П., Керимова Р.Э. и др. Результаты лечения пароксизмальной мерцательной аритмии этацизином. Кардиология 1989; №7: 37-40.

147

Шугушев Х.Х., Сметнев А.С., Розенштраух Л.В. и др. Первый опыт клинического применения нового отечественного антиаритмического препарата – диэтиламинового аналога этмозина – у больных с различными нарушениями ритма сердца. Кардиология 1982; №5: 71-75.

148

Юрявичюс И.А., Розенштраух Л.В., Ундровинас А.И. и др. Действие нового антиаритмического препарата этмозина на силу сокращения, трансмембранный потенциал действия и быстрый входящий натриевый ток предсердной мышцы лягушки. Кардиология 1978; 9: 118-125.

149

Suddoway L.A., Schwartz S.L., Barbey J.T., Woosley R.L. Clinical pharmacokinetics of moricizine. Am J Cardiol 1990; 65: 21D-25D; discussion 68D-71D.

150

Woosley R.L., Morganroth J, Fogoros R.N., et al. Pharmacokinetics of moricizine HCl. Am J Cardiol. 1987; 60: 35F-39F.

151

Mahler S.A., Borland R.M. Clinical development of moricizine as an antiarrhythmic agent. Am J Cardiol 1990; 65:11D-14D; discussion 68D-71D.

152

Morganroth J., Pratt C.M., Kennedy H.L., et al. Efficacy and tolerance of Ethmozine (moricizine HCl) in placebo-controlled trials. Am J Cardiol 1987; 60: 48F-51F.

153

Попова Е.П., Лысковцев В.В., Каверина Н.В. Электрофизиологические эффекты и антиаритмическое действие препаратов I класса этмозина и этацизина в условиях активации парасимпатической нервной системы. Вестник аритмологии 2004; 37: 57-61.

154

Шугушев Х.Х., Малахов В.И., Шестакова Н.В. Первые результаты клинического использования этацизина у пациентов с пароксизмальной фибрилляцией предсердий. Тер. Арх. 1986; 58 (3): 49-52.

155

Connolly S.J. Evidence-based analysis of amiodarone efﬁcacy and safety. Circula-tion 1999; 100: 2025–2034.

156

Kirchhof P., Franz M.R., Bardai A., Wilde A.M. Giant T–U waves precede torsades de pointes in long QT syndrome. A systematic electrocardiographic analysis in patients with acquired and congenital QT prolongation. JACC 2009; 54: 143–149.

157

Kaab S., Hinterseer M., Nabauer M., Steinbeck G. Sotalol testing unmasks altered repolarization in patients with suspected acquired long-QT-syndrome—a case-control pilot study using i.v. sotalol. Eur Heart J 2003; 24: 649–657.

158

Le Heuzey J., De Ferrari G.M., Radzik D., et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efﬁcacy and safety of dronedarone versus amiodarone in patients with persistent atrial ﬁbrillation: the DIONYSOS study. J Cardiovasc Electrophysiol 2010; 21: 597–605.

159

Kober L., Torp-Pedersen C., McMurray J.J., et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008; 358: 2678–2687.

160

Karlson B.W., Torstensson I., Abjorn C., et al. Disopyramide in the maintenance of sinus rhythm after electro-conversion of atrial ﬁbrillation. A placebo-controlled one-year follow-up study. Eur Heart J 1988; 9: 284–290.

161

Crijns H.J., Gosselink A.T., Lie K.I. Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial ﬁbrillation: a randomized, double-blind study. PRODIS Study Group. Cardiovasc Drugs Ther 1996; 10: 145–152.

162

Канорский С.Г., Скибицкий В.В., Федоров А.В. Клиническая эффективность и возможный риск противорецидивной терапии пароксизмальной фибрилляции предсердий: необходимость учета вегетативных влияний на сердце. Вестник аритмологии 1998; №7: 20-26.

163

Bardy G.H., Lee K.L., Mark D.B., et al. Amiodarone or an implantable cardioverter-deﬁbrillator for congestive heart failure. N Engl J Med 2005; 352: 225–237.

164

Piccini J.P., Hasselblad V., Peterson E.D., et al. Comparative efﬁcacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial ﬁbrillation. JACC 2009; 54: 1089–1095.

165

Singh D., Cingolani E., Diamon G.A., Kaul S. Dronedarone for atrial ﬁbrillation: have we expanded the antiar-rhythmic armamentarium. JACC 2010; 55: 1569–1576.

166

Freemantle N., Mitchell S., Orme M., et al. Morbidity and mortality associated with anti-arrhythmic drugs in atrial ﬁbrillation: a systematic review and mixed treatment meta-analysis (abstract). Circulation 2009; 120: S691–S692.

167

Echt D.S., Liebson P.R., Mitchell L.B., et al., Investigators and the CAST investigators. Mortality and morbidity in patients receiving encainide, ﬂecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324: 781–788.

168

Roy D., Talajic M., Dorian P., et al. Amiodarone to prevent recurrence of atrial ﬁbrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000; 342: 913–920.

169

Singh S.N., Fletcher R.D., Fisher S.G., et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Anti-arrhythmic Therapy in Congestive Heart Failure. N Engl J Med 1995; 333: 77–82.

170

Van Gelder I.C., Crijns H.J., Van Gilst W.H., et al. Efﬁcacy and safety of ﬂecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial ﬁbrillation or atrial ﬂutter. Am J Cardiol 1989; 64: 1317–1321.

171

Shah A.N., Mittal S., Sichrovsky T.C., et al. Long-term outcome following successful pulmonary vein isolation: pattern and prediction of very late recurrence. J Cardiovasc Electrophysiol 2008; 19: 661–667.

172

Cappato R., Calkins H., Chen S.A., et al. Worldwide survey on the methods, efﬁcacy, and safety of catheter ablation for human atrial ﬁbrillation. Circulation 2005; 111: 1100–1105.

173

Cappato R., Calkins H., Chen S.A., et al. Prevalence and causes of fatal outcome in catheter ablation of atrial ﬁbrillation. JACC 2009; 53: 1798–1803.

174

Calkins H., Reynolds M.R., Spector P., et al. Treatment of atrial ﬁbrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circ Arrhythm Electrophysiol 2009; 2: 349–361.

175

Noheria A., Kumar A., Wylie J.V. Jr, Josephson M.E. Catheter ablation vs anti-arrhythmic drug therapy for atrial ﬁbrillation: a systematic review. Arch Intern Med 2008; 168: 581–586.

176

Jais P., Cauchemez B., Macle L., et al. Catheter ablation versus antiarrhythmic drugs for atrial ﬁbrillation: the A4 study. Circulation 2008; 118: 2498–2505.

177

Wazni O.M., Marrouche N.F., Martin D.O., et al. Radiofrequency ablation vs antiarrhythmic drugs as ﬁrst-line treatment of symptomatic atrial ﬁbrillation: a randomized trial. JAMA 2005; 293: 2634–2640.

178

Pappone C., Augello G., Sala S., et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial ﬁbrillation: the APAF Study. JACC 2006; 48: 2340–2347.

179

Бокерия Л.А., Ревишвили А.Ш.,Оганов Р.Г. и др. Клинические рекомендации (ВНОА, ВНОК,АССХ) по проведению электрофизиологических исследований, катетерной аблации и применения имплантируемых антиаритмических устройств. Москва, 2009, «Асконлайн», 237-303.

180

Blanc J.J., Almendral J., Brignole M., et al. Consensus document on antithrombotic therapy in the setting of electrophysiological procedures. Europace 2008; 10: 513–527.

181

Piccini J.P., Lopes R.D., Kong M.H., et al. Pulmonary vein isolation for the maintenance of sinus rhythm in patients with atrial ﬁbrillation: a meta-analysis of randomized, controlled trials. Circ Arrhythm Electrophysiol 2009; 2: 626–633.

182

Nair G.M., Nery P.B., Diwakaramenon S., et al. A systematic review of randomized trials comparing radiofrequency ablation with antiarrhythmic medications in patients with atrial ﬁbrillation. J Cardiovasc Electrophysiol 2009; 20: 138–144.

183

Ngaage D.L., Schaff H.V., Mullany C.J., et al. Inﬂuence of preoperative atrial ﬁbrillation on late results of mi-tral repair: is concomitant ablation justiﬁed? Ann Thorac Surg 2007; 84: 434–442; discussion 442–443.

184

Gaita F., Riccardi R., Caponi D., et al. Linear cryoablation of the left atrium versus pulmonary vein cryoisolation in patients with permanent atrial ﬁbrillation and valvular heart disease: correlation of electroanatomic mapping and long-term clinical results. Circulation 2005; 111: 136–142.

185

Cox J.L., Boineau J.P., Schuessler R.B., et al. Successful surgical treatment of atrial ﬁbrillation. Review and clinical update. JAMA 1991; 266: 1976–1980.

186

Gaita F., Riccardi R., Gallotti R. Surgical approaches to atrial ﬁbrillation. Card Electrophysiol Rev 2002; 6: 401–405.

187

Bertaglia E., Tondo C., De Simone A., et al. Does catheter ablation cure atrial fibrillation? Single-procedure outcome of drug-refractory atrial fibrillation ablation: a 6-year multicentre experience. Europace. 2010; 12: 181-177.

188

Cappato R., Calkins H., Chen S.A., et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 2010; 3: 32-38.

189

Oral H., Scharf C., Chugh A., et al. Catheter ablation for paroxysmal atrial fibrillation: segmental pulmonary vein ostial ablation versus left atrial ablation. Circulation 2003; 108: 2355-2360.

190

Pappone C., Rosanio S., Oreto G., et al. Circumferential radiofrequency ablation of pulmonary vein ostia: a new anatomic approach for curing atrial fibrillation. Circulation 2000; 102: 2619-2628.

191

Pappone C., Rosanio S., Augello G., et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. JACC 2003; 42: 185-197.

192

Reynolds M.R., Zimetbaum P., Josephson M.E., et al. Cost-effectiveness of radiofrequency catheter ablation compared with antiarrhythmic drug therapy for paroxysmal atrial fibrillation. Circ Arrhythm Electrophysiol 2009; 2: 362-369.

193

Stabile G., Bertaglia E., Senatore G., et al. Catheter ablation tre3tment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study). Eur Heart J 2006; 27: 216-221.

194

Terasawa T., Balk E.M., Chung M., et al. Systematic review: comparative effectiveness of radiofrequency catheter ablation for atrial fibrillation. Ann Intern Med 2009; 151: 191-202.

195

Wazni O.M., Marrouche N.F., Martin D.O., et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 2005; 293: 2634-2640.

196

Wilber D.J., Pappone C., Neuzil P., et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA 2010; 303: 333-340.

197

Calo L., Lamberti F., Loricchio M.L., et al. Left atrial ablation versus biatrial ablation for persistent and permanent atrial fibrillation: a prospective and randomized study. J Am Coll Cardiol 2006; 47: 2504-2512.

198

Chen M.S., Marrouche N.F., Khaykin Y., et al. Pulmonary vein isolation for the treatment of atrial fibrillation in patients with impaired systolic function. J Am Coll Cardiol 2004; 43: 1004-1009.

199

Gentlesk P.J., Sauer W.H., Gerstenfeld E.P., et al. Reversal of left ventricular dysfunction following ablation of atrial fibrillation. J Cardiovasc Electrophysiol 2007; 18: 9-14.

200

Haissaguerre M., Hocini M., Sanders P., et al. Catheter ablation of long-lasting persistent atrial fibrillation: clinical outcome and mechanisms of subsequent arrhythmias. J Cardiovasc Electrophysiol 2005; 16: 1138-1347.

201

Hsu L.F., Jais P., Sanders P., et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 2004; 351: 2373-2383.

202

Khan M.N., Jais P., Cummings J., et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med 2008; 359: 1778-1785.

203

Lang C.C., Santinelli V., Augello G., et al. Transcatheter radiofrequency ablation of atrial fibrillation in patients with mitral valve prostheses and enlarged atria: safety, feasibility, and efficacy. JACC 2005; 45: 868-872.

204

Oral H., Pappone C., Chugh A., et al. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med 2006; 354: 934-941.

205

Takahashi Y., O’Neill M.D., Hocini M., et al. Effects of stepwise ablation of chronic atrial fibrillation on atrial electrical and mechanical properties. JACC 2007; 49: 1306-1314.

206

Tondo C., Mantica M., Russo G., et al. Pulmonary vein vestibule ablation for the control of atrial fibrillation in patients with impaired left ventricular function. Pacing Clin Electrophysiol 2006; 29: 962-970.

207

Calkins H., Brugada J., Packer D.L., et al. HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. a report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 2007; 4: 816-861.

208

Al-Khatib S.M., Calkins H., Eloff B.C., et al. Planning the Safety of Atrial Fibrillation Ablation Registry Initiative (SAFARI) as a Collaborative Pan- Stakeholder Critical Path Registry Model: a Cardiac Safety Research Consortium «Incubator» Think Tank. Am Heart J 2010; 159: 17-24.

209

Wann L.S., Curtis A.B., Januaru C.T., et al. 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline). Heart Rhythm 2011; 8: 158-176.

210

Savelieva I., Camm A.J. Is there any hope for angiotensin-converting enzyme inhibitors in atrial ﬁbrillation? Am Heart J 2007; 154: 403–406.

211

Goette A., Staack T., Rocken C., et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial ﬁbrillation. J Am Coll Cardiol 2000; 35: 1669–1677. 213. Schneider M.P., Hua T.A., Bohm M., et al. Prevention of atrial ﬁbrillation by renin–angiotensin system inhibition a meta-analysis. JACC 2010; 55: 2299–2307.

212

Healey J.S., Baranchuk A., Crystal E., et al. Prevention of atrial ﬁbrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. JACC 2005; 45: 1832–1839.

213

Jibrini M.B., Molnar J., Arora R.R. Prevention of atrial ﬁbrillation by way of abrogation of the renin–angiotensin system: a systematic review and meta-analysis. Am J Ther 2008; 15: 36–43.

214

Anand K., Mooss A.N., Hee T.T., Mohiuddin S.M. Meta-analysis: inhibition of renin– angiotensin system prevents new-onset atrial ﬁbrillation. Am Heart J 2006; 152: 217–222.

215

Ducharme A., Swedberg K., Pfeffer M.A., et al. Prevention of atrial ﬁbrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006; 151: 985–991.

216

Wachtell K., Lehto M., Gerdts E., et al. Angiotensin II receptor blockade reduces new-onset atrial ﬁbrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. JACC 2005; 45: 712–719.

217

Schmieder R.E., Kjeldsen S.E., Julius S., et al. Reduced incidence of new-onset atrial ﬁbrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens 2008; 26: 403–411.

218

Madrid A.H., Bueno M.G., Rebollo J.M., et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial ﬁbrillation: a prospective and randomized study. Circulation 2002; 106: 331–336.

219

Ueng K.C., Tsai T.P., Yu W.C., et al. Use of enalapril to facilitate sinus rhythm maintenance after external car-dioversion of long-standing persistent atrial ﬁbrillation. Results of a prospective and controlled study. Eur Heart J 2003; 24: 2090–2098.

220

Tveit A., Seljeﬂot I., Grundvold I., et al. Effect of candesartan and various inﬂammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial ﬁbrillation. Am J Cardiol 2007; 99: 1544–1548.

221

Yin Y., Dalal D., Liu Z., et al. Prospective randomized study comparing amiodarone vs. amiodarone plus losar-tan vs. amiodarone plus perindopril for the prevention of atrial ﬁbrillation recurrence in patients with lone paroxysmal atrial ﬁbrillation. Eur Heart J 2006; 27: 1841–1846.

222

Belluzzi F., Sernesi L., Preti P., et al. Prevention of recurrent lone atrial ﬁbrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients. J Am Coll Cardiol 2009; 53: 24–29.

223

Disertori M., Latini R., Barlera S., et al. Valsartan for prevention of recurrent atrial ﬁbrillation. N Engl J Med 2009; 360: 1606–1617.

224

Savelieva I., Camm A.J. Statins and polyunsaturated fatty acids for treatment of atrial ﬁbrillation. Nat Clin Pract Cardiovasc Med 2008; 5: 30–41.

225

Savelieva I., Kourliouros A., Camm J. Primary and secondary prevention of atrial ﬁbrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance. Naunyn Schmiedebergs Arch Pharma-col 2010; 381: 1–13.

226

Santangeli P., Ferrante G., Pelargonio G., et al. Usefulness of statins in preventing atrial ﬁbrillation in patients with permanent pacemaker: a systematic review. Europace 2010; 12: 649–654.

227

Patti G., Chello M., Candura D., et al. Randomized trial of atorvastatin for reduction of postoperative atrial ﬁbrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MY-ocardial Dysrhythmia After cardiac surgery) study. Circulation 2006; 114: 1455–1461.

228

Liakopoulos O.J., Choi Y.H., Kuhn E.W., et al. Statins for prevention of atrial ﬁbrillation after cardiac surgery: a systematic literature review. J Thorac Cardiovasc Surg 2009; 138: 678–686 e1.

229

Almroth H., Hoglund N., Boman K., et al. Atorvastatin and persistent atrial ﬁbrillation following cardioversion: a randomized placebo-controlled multicentre study. Eur Heart J 2009; 30: 827–833.

230

Fauchier L., Pierre B., de Labriolle A., et al. Antiarrhythmic effect of statin therapy and atrial ﬁbrillation: a meta-analysis of randomized controlled trials. JACC 2008; 51: 828–835.

231

Liu T., Li L., Korantzopoulos P., et al. Statin use and development of atrial ﬁbrillation: a systematic review and meta-analysis of randomized clinical trials and observational studies. Int J Cardiol 2008; 126: 160–170.

232

Saravanan P., Bridgewater B., West A.L., et al. Omega-3 fatty acid supplementation does not reduce risk of atrial ﬁbrillation after coronary artery bypass surgery: a randomized, double-blind, placebo-controlled clinical trial. Circ Arrhythm Electrophysiol 2009; 3: 46–53.

233

Heidarsdottir R., Arnar D.O., Skuladottir G.V., et al. Does treatment with n-3 polyunsaturated fatty acids prevent atrial ﬁbrillation after open heart surgery? Europace 2010; 12: 356–363.

234

Bertini M., Borleffs J.W., Delgado V., et al. Prediction of atrial ﬁbrillation in patients with implantable car-dioverter-deﬁbrillator and heart failure. Eur J Heart Fail 2010; in press.

235

Fauchier L., Grimard C., Pierre B., et al. Comparison of beta blocker and digoxin alone and in combination for management of patients with atrial ﬁbrillation and heart failure. Am J Cardiol 2009; 103: 248–254.

236

Nasr I.A., Bouzamondo A., Hulot J.S., et al. Prevention of atrial ﬁbrillation onset by beta-blocker treatment in heart failure: a meta-analysis. Eur Heart J 2007; 28: 457–462.

237

Khand A.U., Rankin A.C., Martin W., et al. Carvedilol alone or in combination with digoxin for the management of atrial ﬁbrillation in patients with heart failure? JACC 2003; 42: 1944–1951.

238

Farshi R., Kistner D., Sarma J.S., et al. Ventricular rate control in chronic atrial ﬁbrillation during daily activity and programmed exercise: a crossover open-label study of ﬁve drug regimens. JACC 1999; 33: 304–310.

239

Kumar A. Intravenous amiodarone for therapy of atrial ﬁbrillation and ﬂutter in critically ill patients with severely depressed left ventricular function. South Med J 1996; 89: 779–785.

240

Gasparini M., Regoli F., Galimberti P., et al. Cardiac resynchronization therapy in heart failure patients with atrial ﬁbrillation. Europace 2009; 11, Suppl 5: v82–v86.

241

Deedwania P.C., Singh B.N., Ellenbogen K., et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial ﬁbrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation 1998; 98: 2574–2579.

242

Shelton R.J., Clark A.L., Goode K., et al. A randomised, controlled study of rate versus rhythm control in patients with chronic atrial ﬁbrillation and heart failure: (CAFE-II Study). Heart 2009; 95: 924–930.

243

Eliahou H.E., Silverberg D.S., Reisin E., et al. Propranolol for the treatment of hypertension in pregnancy. Br J Obstet Gynaecol 1978; 85: 431–436.

244

Aizer A., Gaziano J.M., Cook N.R., et al. Relation of vigorous exercise to risk of atrial ﬁbrillation. Am J Cardiol 2009; 103: 1572–1577.

245

Mozaffarian D., Furberg C.D., Psaty B.M., Siscovick D. Physical activity and inci-dence of atrial ﬁbrillation in older adults: the cardiovascular health study. Circulation 2008; 118: 800–807.

246

Mont L., Sambola A., Brugada J., et al. Long-lasting sport practice and lone atrial ﬁbrillation. Eur Heart J 2002; 23: 477–482.

247

Heidbuchel H., Anne W., Willems R., et al. Endurance sports is a risk factor for atrial ﬁbrillation after ablation for atrial ﬂutter. Int J Cardiol 2006; 107: 67–72.

248

Heidbuchel H., Panhuyzen-Goedkoop N., Corrado D., et al. Recommendations for participation in leisure-time physical activity and competitive sports in patients with arrhythmias and potentially arrhythmogenic conditions Part I: supraventricular arrhythmias and pacemakers. Eur J Cardiovasc Prev Rehabil 2006; 13: 475–484.

249

Calvo N., Mont L., Tamborero D., et al. Efﬁcacy of circumferential pulmonary vein ablation of atrial ﬁbrillation in endurance athletes. Europace 2010; 12: 30–36.

250

Wyse D.G. Pharmacotherapy for rhythm management in elderly patients with atrial ﬁbrillation. J Interv Card Electrophysiol 2009; 25: 25–29.

251

Bates S.M., Greer I.A., Pabinger I., et al. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 844S–886S.

252

Crystal E., Garﬁnkle M.S., Connolly S.S., et al. Interventions for preventing post-operative atrial ﬁbrillation in patients undergoing heart surgery. Cochrane Database Syst Rev 2004; 4: CD003611.

253

Burgess D.C., Kilborn M.J., Keech A.C. Interventions for prevention of post-operative atrial ﬁbrillation and its complications after cardiac surgery: a meta-analysis. Eur Heart J 2006; 27: 2846–2857.

254

Bagshaw S.M., Galbraith P.D., Mitchell L.B., et al. Prophylactic amiodarone for prevention of atrial ﬁbrillation after cardiac surgery: a meta-analysis. Ann Thorac Surg 2006; 82: 1927–1937.

255

Patel A.A., White C.M., Gillespie E.L., et al. Safety of amiodarone in the prevention of postoperative atrial ﬁbrillation: a meta-analysis. Am J Health Syst Pharm 2006; 63: 829–837.

256

Buckley M.S., Nolan P.E. Jr, Slack M.K., et al. Amiodarone prophylaxis for atrial ﬁbrillation after cardiac surgery: meta-analysis of dose response and timing of initiation. Pharmacotherapy 2007; 27: 360–368.

257

Miller S., Crystal E., Garﬁnkle M., et al. Effects of magnesium on atrial ﬁbrillation after cardiac surgery: a meta-analysis. Heart 2005; 91: 618–623.

258

Ho K.M., Tan J.A. Beneﬁts and risks of corticosteroid prophylaxis in adult cardiac surgery: a dose–response meta-analysis. Circulation 2009; 119: 1853–1866.

259

Daoud E.G., Snow R., Hummel J.D., et al. Temporary atrial epicardial pacing as prophylaxis against atrial ﬁbrillation after heart surgery: a meta-analysis. J Cardiovasc Electrophysiol 2003; 14: 127–132.

260

Dunning J., Treasure T., Versteegh M., Nashef S.A. Guidelines on the prevention and management of de novo atrial ﬁbrillation after cardiac and thoracic surgery. Eur J Cardiothorac Surg 2006; 30: 852–872.

261

Daoud E.G. Management of atrial ﬁbrillation in the post-cardiac surgery setting. Cardiol Clin 2004; 22:159–166.

262

Mathew J.P., Fontes M.L., Tudor I.C., et al. A multicenter risk index for atrial ﬁbrillation after cardiac surgery. JAMA 2004; 291: 1720–1729.

263

Wellens H.J. Should catheter ablation be performed in asymptomatic patients with Wolff–Parkinson–White syndrome? When to perform catheter ablation in asymptomatic patients with a Wolff–Parkinson–White electrocardiogram. Circulation 2005; 112: 2201–2297; discussion 2216.

264

Pappone C., Santinelli V., Manguso F., et al. A randomized study of prophylactic catheter ablation in asymptomatic patients with the Wolff–Parkinson–White syndrome. N Engl J Med 2003; 349: 1803–1811.

265

Chen M.S., McCarthy P.M., Lever H.M., et al. Effectiveness of atrial ﬁbrillation surgery in patients with hyper-trophic cardiomyopathy. Am J Cardiol 2004; 93: 373–375.

266

Maron B.J., Olivotto I., Bellone P., Conte et al. Clinical proﬁle of stroke in 900 patients with hypertrophic car-diomyopathy. JACC 2002; 39: 301–307.

The authors declare that there are no conflicts of interest present.